GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » ROE % Adjusted to Book Value

Vivos Therapeutics (Vivos Therapeutics) ROE % Adjusted to Book Value : -133.67% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics ROE % Adjusted to Book Value?

Vivos Therapeutics's ROE % for the quarter that ended in Mar. 2024 was -3,031.62%. Vivos Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 22.68. Vivos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -133.67%.


Vivos Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Vivos Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics ROE % Adjusted to Book Value Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -27.13 -47.08 -81.45 -9.38

Vivos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.12 -67.04 -6.16 -134.24 -133.67

Competitive Comparison of Vivos Therapeutics's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Vivos Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Therapeutics's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's ROE % Adjusted to Book Value falls into.



Vivos Therapeutics ROE % Adjusted to Book Value Calculation

Vivos Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-521.22% / 55.54
=-9.38%

Vivos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-3,031.62% / 22.68
=-133.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129